-
1
-
-
0041732120
-
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
-
DOI 10.1161/01.CIR.0000087404.53661.F8
-
Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-83. (Pubitemid 37099984)
-
(2003)
Circulation
, vol.108
, Issue.10
, pp. 1176-1183
-
-
Mahaffey, K.W.1
Granger, C.B.2
Nicolau, J.C.3
Ruzyllo, W.4
Weaver, W.D.5
Theroux, P.6
Hochman, J.S.7
Filloon, T.G.8
Mojcik, C.F.9
Todaro, T.G.10
Armstrong, P.W.11
-
2
-
-
0042917638
-
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
-
DOI 10.1161/01.CIR.0000087447.12918.85
-
Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-90. (Pubitemid 37099985)
-
(2003)
Circulation
, vol.108
, Issue.10
, pp. 1184-1190
-
-
Granger, C.B.1
Mahaffey, K.W.2
Weaver, W.D.3
Theroux, P.4
Hochman, J.S.5
Filloon, T.G.6
Rollins, S.7
Todaro, T.G.8
Nicolau, J.C.9
Ruzyllo, W.10
Armstrong, P.W.11
-
3
-
-
33845981823
-
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial
-
APEX AMI Investigators
-
APEX AMI InvestigatorsArmstrong PW, Granger CB, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51.
-
(2007)
JAMA
, vol.297
, pp. 43-51
-
-
Armstrong, P.W.1
Granger, C.B.2
-
4
-
-
2442613898
-
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial
-
DOI 10.1001/jama.291.19.2319
-
Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 2004;291:2319-27. (Pubitemid 38656298)
-
(2004)
Journal of the American Medical Association
, vol.291
, Issue.19
, pp. 2319-2327
-
-
Verrier, E.D.1
Shernan, S.K.2
Taylor, K.M.3
De Van, W.F.4
Newman, M.F.5
Chen, J.C.6
Carrier, M.7
Haverich, A.8
Malloy, K.J.9
Adams, P.X.10
Todaro, T.G.11
Mojcik, C.F.12
Rollins, S.A.13
Levy, J.H.14
-
5
-
-
79959361476
-
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials
-
Sep 27 in press, doi:10.1016/j.jtcvs.2010.08.035
-
Smith PK, Shernan SK, Chen JC, et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg Sep 27 in press, doi:10.1016/j.jtcvs.2010.08.035.
-
J Thorac Cardiovasc Surg
-
-
Smith, P.K.1
Shernan, S.K.2
Chen, J.C.3
-
6
-
-
0029029540
-
The fluid-phase SC5b-9 terminal complement complex binds to the GPIIb/IIIa complex of thrombin-stimulated human blood platelets inhibiting platelet aggregation
-
Røger M, Høgåsen K, Holme PA, et al. The fluid-phase SC5b-9 terminal complement complex binds to the GPIIb/IIIa complex of thrombin-stimulated human blood platelets inhibiting platelet aggregation. Platelet 1995;6:160-8.
-
(1995)
Platelet
, vol.6
, pp. 160-168
-
-
Røger, M.1
Høgåsen, K.2
Holme, P.A.3
-
7
-
-
78651422977
-
Pexelizumab may be hazardous to those with STsegment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors
-
Lin GM, Chu KM, Han CL. Pexelizumab may be hazardous to those with STsegment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors. Int J Cardiol 2011;146:280-2.
-
(2011)
Int J Cardiol
, vol.146
, pp. 280-282
-
-
Lin, G.M.1
Chu, K.M.2
Han, C.L.3
-
8
-
-
0023020183
-
The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations
-
Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-82.
-
(1986)
J Pers Soc Psychol
, vol.51
, pp. 1173-1182
-
-
Baron, R.M.1
Kenny, D.A.2
-
9
-
-
20244381088
-
Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits
-
DOI 10.1016/S0003-4975(97)01347-7, PII S0003497597013477
-
Aldea GS, O'Gara P, Shapira OM, et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg 1998;65:425-33. (Pubitemid 28083339)
-
(1998)
Annals of Thoracic Surgery
, vol.65
, Issue.2
, pp. 425-433
-
-
Aldea, G.S.1
O'Gara, P.2
Shapira, O.M.3
Treanor, P.4
Osman, A.5
Patalis, E.6
Arkin, C.7
Diamond, R.8
Babikian, V.9
Lazar, H.L.10
Shemin, R.J.11
-
10
-
-
77957884628
-
Ethics in the authorship and publishing of scientific articles
-
Shewan LG and Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.
-
(2010)
Int J Cardiol
, vol.144
, pp. 1-2
-
-
Shewan, L.G.1
Coats, A.J.2
|